[1] Czul F, Bhamidimarri KR. Noninvasive markers to assess liver fibrosis. J ClinGastroenterol, 2016, 50: 445-447.
[2] Shiha G, Ibrahim A, Helmy A, et al. Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update. Hepatol Int, 2017, 11: 1-30.
[3] European Association for the Study of the Liver, Asociacion Latinoamericana Para el Estudio Del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol, 2015, 63: 237-264.
[4] World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva: WHO Press, 2015: 25-35.
[5] Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int, 2016, 10: 1-98.
[6] Lampertico P, Agarwal K, Berg T, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol, 2017, 67: 370-398.
[7] Lemoine M, Shimakawa Y, Nayagam S, et al. The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa. Gut, 2016,65: 1369-1376.
[8] Wang RQ, Zhang QS, Zhao SX, et al. Gamma-glutamyl transpeptidase to platelet ratio index is a good noninvasive biomarker for predicting liver fibrosis in Chinese chronic hepatitis B patients. J Int Med Res, 2016, 44: 1302-1313.
[9] Lu XJ, Li XH, Yuan ZX, et al. Assessment of liver fibrosis with the gamma-glutamyltranspeptidase to platelet ratio: a multicentre validation in patients with HBV infection. Gut, 2018,67:1903-1904.
[10] Liu DP, Lu W, Zhang ZQ, et al. Comparative evaluation of GPR versus APRI and FIB-4 in predicting different levels of liver fibrosis of chronic hepatitis B. J Viral Hepat, 2018,25:581-589. |
